BIIB241227P105000
- 0.00
- 0.000.00%
Biogen Newsroom
17 Analysts Assess Biogen: What You Need To Know
Piper Sandler Downgrades Biogen to Neutral, Lowers Price Target to $138
Biogen Analyst Ratings
Piper Sandler Downgrades Biogen, Slashes PT by $177 Amid Transition Challenges
These Battered S&P 500 Stocks Could Be Ripe for a Turnaround in 2025
Express News | Biogen : Piper Sandler Cuts to Neutral From Overweight
Why Biogen Inc. (BIIB) Is a Top Value Stock for the Long-Term
These Are the Best and Worst Stocks This Year
Market Falling Monday, With Few Santa Clause 'Rally' Days Left | Live Stock
Biogen Inc. (BIIB): Among the Cheap Healthcare Stocks to Buy Heading Into 2025
Weekly Buzz: So far, Santa is Letting us Down
Friday Market Pulls Back, Led by Mag Seven Decline | Live Stock
Investors Aren't Entirely Convinced By Biogen Inc.'s (NASDAQ:BIIB) Earnings
2024's Top and Bottom Nasdaq-100 Performers Includes NVDA, APP, INTC, MRNA, and More
Biogen Faces Multiple Analyst Downgrades in December 2024
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
Materials, Software Stocks Are Best Poised for H1 Outperformance: Goldman Sachs
Leerink Partners Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $290
BMO Capital Downgrades Biogen(BIIB.US) to Hold Rating, Cuts Target Price to $164
Biogen's Challenges and Cautious Outlook: Hold Rating Amid Revenue Growth Struggles and Neurology Market Hurdles